CN111153882A - 一种来那替尼和汉黄芩素共晶体及其应用 - Google Patents
一种来那替尼和汉黄芩素共晶体及其应用 Download PDFInfo
- Publication number
- CN111153882A CN111153882A CN202010032446.8A CN202010032446A CN111153882A CN 111153882 A CN111153882 A CN 111153882A CN 202010032446 A CN202010032446 A CN 202010032446A CN 111153882 A CN111153882 A CN 111153882A
- Authority
- CN
- China
- Prior art keywords
- wogonin
- neratinib
- complex
- compound
- acetonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 title claims abstract description 42
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 229950008835 neratinib Drugs 0.000 claims abstract description 44
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 239000013078 crystal Substances 0.000 claims abstract description 19
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 18
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 18
- 230000005496 eutectics Effects 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 201000011510 cancer Diseases 0.000 claims abstract description 8
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims abstract 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33
- 239000002904 solvent Substances 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000012047 saturated solution Substances 0.000 claims description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 230000001093 anti-cancer Effects 0.000 abstract description 5
- 239000006069 physical mixture Substances 0.000 abstract description 4
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 36
- 238000011580 nude mouse model Methods 0.000 description 15
- 241000699660 Mus musculus Species 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000013392 nude mouse xenograft model Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- -1 for example Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- VXZCUHNJXSIJIM-MEBGWEOYSA-N (z)-but-2-enedioic acid;(e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound OC(=O)\C=C/C(O)=O.C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 VXZCUHNJXSIJIM-MEBGWEOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007936 buccal or sublingual tablet Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000007613 slurry method Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Pregnancy & Childbirth (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种用于预防和/或治疗癌症的药物复合物及其应用,所述药物复合物以来那替尼和汉黄芩素作为活性成分,其中来那替尼和汉黄芩素以共晶体的形式存在。本发明的复合物有良好的抗癌作用,尤其是对乳腺癌,来那替尼和汉黄芩素的共晶体提高了难溶性药物来那替尼的溶解性和生物利用度,与两者的物理混合物相比有更显著的抗癌效果。
Description
技术领域
本发明涉及医药技术领域,具体涉及一种用于治疗癌症,特别是乳腺癌的药物复合物,所述药物复合物以来那替尼和汉黄芩素以活性成分,两者以共晶体的形式存在。
背景技术
乳腺癌是女性最常见的恶性肿瘤之一。据世界卫生组织( WHO) 2017 年2月提供的报道,2015年全世界新发现的妇女乳腺癌患者约120 万例,死亡57.1 万例,中国每年有16.9万例患者被新确诊为乳腺癌,其中20%~30%人罹患HER2阳性乳腺癌。近年来世界各国乳腺癌发病率有迅速上升的趋势,已居女性恶性肿瘤死亡率首位。
来那替尼(Neratinib maleate)一种口服有效的、不可逆的泛人表皮生长因子受体(EGFR)抑制剂,有效成分为来那替尼游离碱。化学名为( E)-N- { 4-[[3-氯-4-[(吡啶-2-基)-甲氧基]苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基}-4-(二甲基氨基)-丁- 2-烯酰胺。来那替尼( neratinib) 通过阻止EGFR、HER1、HER2 和HER4 信号通路转导,发挥抗癌作用。然而,来那替尼的共同缺陷在于水溶性差,存在溶解速度慢、体外溶解度低、生物利用度低的缺点,使药物的吸收和治疗效果都受到影响。
汉黄芩素(wogonin)是黄酮类化学成分,能够激活细胞外调节蛋白激酶(ERK)并抑制PI3K-Akt-Survivin通路,引起乳腺癌、结肠癌、肝癌、肺癌等多种癌症细胞凋亡。肿瘤坏死因子相关凋亡诱导配体(TRAIL)能有效诱导肿瘤细胞凋亡而对正常细胞无害,但是许多肿瘤细胞能够抵抗TRAIL引起的凋亡。汉黄芩素通过抑制c-FLIP(cellular FADD-like IL-1β-concerting enzyme-inhibitory protein)蛋白表达和促进TRAIL-R2蛋白表达,从而抑制肿瘤细胞对TRAIL的抵抗。
共晶技术是在不改变药物活性成分的前提下可以提高药物溶解度,从而改善药物吸收,提高生物利用度。共晶技术是改善难溶性药物的溶解度的有效方法。其原理是使共晶形成物与药物API中的羟基、氨基等基团通过氢键形成新的结晶形式,原有的晶格堆积和分子排列方式发生改变,形成共晶体。
发明内容
本发明意外的发现,黄酮类化合物汉黄芩素不但本身具有抗癌作用,而且可以作为共晶形成物与来那替尼形成共晶体,两者的共晶体不但显著改善来那替尼的溶解性,进而提高来那替尼的生物利用度,而且来那替尼和汉黄芩素两种药物之间相互作用,协同增效,与简单的物理混合相比,具有显著提高的抗癌活性。
因此,本发明旨在提供一种以来那替尼和汉黄芩素作为活性成分的复合物,其中所述来那替尼和汉黄芩素以共晶体的形式存在。所述复合物用于预防和/或治疗癌症,特别是乳腺癌。
本发明一方面提供一种来那替尼和汉黄芩素的复合物,其中所述来那替尼和汉黄芩素以共晶体的形式存在,其中,来那替尼和汉黄芩素的摩尔比为1:5至5:1,优选摩尔比为1:1。两种药物以上述摩尔比形成非共价结合形成的共晶体复合物。
进一步的,所述来那替尼-汉黄芩素共晶体复合物的X射线粉末衍射图谱中,衍射角度2θ包含在7.565°、9.295°、13.250°、19.030°、20.145°、22.078°、24. 788°以及27.500°位置的衍射峰。
进一步的,所述来那替尼-汉黄芩素共晶体复合物的差示扫描量热(DSC)法测定该共晶体的熔点为257.5℃。
另一方面,本发明还提供了一种制备来那替尼-汉黄芩素共晶体复合物的方法,其包括:以来那替尼和汉黄芩素为原料,采用溶剂结晶法制得来那替尼-汉黄芩素共晶体复合物。
进一步的,其中所采用的溶剂为乙腈或含乙腈的混合溶剂。
进一步的,所述溶剂结晶法中采用的溶剂选自乙腈,或乙腈与甲醇、乙醇、乙酸乙酯、氯仿中的一种或两种以上按任意比例混合的混合溶剂系统。优选的溶剂为乙腈。
进一步的,具体的制备方法为:将来那替尼和汉黄芩素分别各自制备成第一饱和溶液和第二饱和溶液;将第一饱和溶液和第二饱和溶液分别过滤后混合,并静置挥发得到沉淀,将所述沉淀过滤、洗涤、干燥,得到白色结晶颗粒,即为来那替尼和汉黄芩素共晶体复合物。
另一方面,本发明还提供了一种药物组合物,其包含所述来那替尼和汉黄芩素的共晶体复合物以及药学上可接受的载体。
进一步的,所述药物组合物用于预防和/或治疗癌症。所述癌症优选乳腺癌。
所述药物组合物的给药方式,例如口服、直肠、肠胃外、局部、或通过静脉内、肌内、胸骨内或皮下注射、或以适于吸入的形式。只要合适,制剂可以方便地以个别剂量单位存在并可通过药学领域中熟知的任何方法进行制备。根据已知的和已确定的实践,所述化合物一般将与一种或多种药学上可接受的成分一起配制。因此,药物组合物可被配制成液体、粉末、可注射溶液、悬浮剂、栓剂等。
用于口服的制剂可被提供为片剂或硬胶囊,其中所述化合物与惰性固体稀释剂例如碳酸钙、磷酸钙或高岭土混合,或者提供为软明胶胶囊,其中活性成分与水或可混溶溶剂如丙二醇、PEG和乙醇、或油质介质如花生油、液体石蜡或橄榄油混合。
对于在口中的局部给药,药物组合物可采取以常规方式配制的颊部或舌下片剂、滴剂或锭剂。
所述化合物可被配制,用于通过注射、便利的静脉内、肌内或皮下注射的肠胃外给药,例如通过弹丸注射或连续静脉输注。注射制剂可以单位剂型存在,例如,于加入防腐剂安瓿或多剂量容器中。药物组合物可采取这类形式,例如在水性载体中的悬浮剂、溶液或乳剂,且可含有配制剂,如悬浮剂、稳定剂和/或分散剂。可选地,所述化合物可以以粉末形式,用于在使用前与合适的载体如无菌无热源水一起构建。
对于鼻内给药,所述化合物可被使用,例如作为液体喷雾剂、作为粉末或以滴剂形式。
对于吸入给药,所述化合物可方便地以通过加压包装或喷雾器的气溶胶气雾剂包装的形式进行输送,并使用合适的推进剂,例如二氯二氟甲烷、三氯氟代甲烷、二氯四氟乙烷、四氟乙烷、七氟丙烷、二氧化碳或其它合适的气体。
有益效果
(1)来那替尼和汉黄芩素的共晶体复合物与单独的来那替尼相比溶解性显著增加,获得了提高的生物利用度。
(2)本发明通过人源乳腺癌BT474裸鼠异种移植模型证明,来那替尼和汉黄芩素的共晶体复合物与来那替尼和汉黄芩素的简单物理混合物相比,能够更有效的抑制肿瘤生长,缩小肿瘤体积,两者具有统计学差异。
附图说明
图1是来那替尼的结构式;
图2是汉黄芩素的结构式;
图3是实施例1的来那替尼和汉黄芩素共晶体复合物的粉末X射线衍射图;
图4是实施例1的来那替尼和汉黄芩素共晶体复合物的差示扫描量热法分析(DSC)图;
图5是实施例1的来那替尼和汉黄芩素共晶体复合物以及来那替尼的溶出度曲线。
具体实施方式
在下文中更详细地描述了本发明以有助于对本发明的理解。
实施例1
将来那替尼约186mg和汉黄芩素约96mg(摩尔比1:1 )分别溶解在2~3mL乙腈溶剂里,加热到46℃,分别使用孔径为0.22μm的微孔滤膜过滤,然后混合两种溶液,室温静置挥发24h,然后洗涤过滤,常温下真空干燥24h,得到白色结晶状固体144mg ,产率约为51.0%。
实施例2
将来那替尼约372mg和汉黄芩素约96mg(摩尔比2:1 )分别溶解在2~3mL乙腈-甲醇溶剂里,加热到46℃,分别使用孔径为0.22μm的微孔滤膜过滤,然后混合两种溶液,室温静置挥发24h,然后洗涤过滤,常温下真空干燥24h,得到白色结晶状固体193mg ,产率约为41.2%。
实施例3
将来那替尼约186mg和汉黄芩素约190mg(摩尔比1:2 )分别溶解在2~3mL乙腈-甲醇溶剂里,加热到46℃,分别使用孔径为0.22μm的微孔滤膜过滤,然后混合两种溶液,室温静置挥发24h,然后洗涤过滤,常温下真空干燥24h,得到白色结晶状固体170mg ,产率约为45.2%。
实施例4
对实施例1所获得的来那替尼和汉黄芩素的共晶体复合物进行测定和表征。
采用Bruker D8 Advance衍射仪测定实施例1中获得的共晶体的粉末衍射图,测定条件如下:Cu Kα,40kV,40mV为光源,步长0 .0128°,扫描范围3~45°,室温。
其X射线粉末衍射在衍射角度2θ(误差±0 .1度)在7.565°、9.295°、13.250°、19.030°、20.145°、22.078°、24. 788°以及27.500°处具有特征峰,如图3。
采用TA Q2000差示扫描量热仪测定实施例1中获得的共晶体,测定条件如下:大约2mg的样品用铝盘封装,加热温度范围25~300℃,升温速率10 .0℃/min,吹扫气为50mL/min的氮气,温度校准使用NIST铟金属进行。该共晶体的差示扫描热分析图( DSC )如图4所示,该共晶体熔点为257.5℃。
实施例5
对实施例1所获得的来那替尼和汉黄芩素的共晶体复合物进行体外溶出度试验。
取来那替尼或含有相同药量来那替尼和汉黄芩素的共晶体复合物20 mg,在温度37℃、转速75 r·min-1、浆法的条件下实验。以pH = 1.0 的盐酸为溶出介质,分别于5、10、20、30、45、60 和90 min 取样5 mL,使用0.45μm 滤膜将取出液体过滤,取续滤液平行3 次测定A 值,根据标准曲线计算出浓度及溶出度。结果如图5所示。
实施例6
来那替尼和汉黄芩素的共晶体复合物对人源乳腺癌BT474裸鼠异种移植模型肿瘤生长的抑制作用研究
BALB/c 裸鼠30 只,雌性,体重18~22 g。人源乳腺癌BT474 细胞购自中国科学院菌种保藏中心。
人源乳腺癌BT474 裸鼠异种移植模型的建立
人源乳腺癌BT474 细胞用含10% 灭活胎牛血清、120 U/mL 青霉素、120 g/mL 链霉素和3 mmol/L谷氨酰胺的DMEM 培养基于37 ℃、5% CO2 培养箱中培养。正常传代培养,每周传代2 次,将处于对数生长期的肿瘤细胞接种于裸鼠体内。肿瘤细胞接种前1 d,每只裸鼠左侧肩胛部皮下植入雌激素片(17-estradiol),植入后第二天在裸鼠右侧前胁肋部皮下接种PBS 重悬的人源乳腺癌BT474 肿瘤细胞7×107 个/mL,共接种60 只。人源乳腺癌BT474细胞接种第18 天测量每只裸鼠的肿瘤体积,选取肿瘤体积为100~160 mm3的24只裸鼠,随机分为以下3 组,每组8 只:模型组(0.5%羟丙基甲基纤维素溶液灌胃)、来那替尼和汉黄芩素物理混合组(来那替尼和汉黄芩素按照摩尔比1:1混合,80 mg/kg灌胃)、来那替尼和汉黄芩素的共晶体复合物组(实施例1制备得到的共晶体,80 mg/kg灌胃)。各剂量组受试药物均用0.5%羟丙基甲基纤维素溶液按所需浓度配制,从肿瘤细胞接种第20 天开始灌胃给药,每天1 次,连续给药14天。
裸鼠肿瘤生长的测量
分别于给药前以及给药后7 天、14天测量肿瘤的长径和短径并称量体重,于末次给药后24 h 脱颈处死裸鼠,剥离肿瘤并称重。计算肿瘤体积(TV)、相对肿瘤体积(RTV)、及肿瘤抑制率(IR),计算公式:TV=0.5×长径×短径;RTV=TVt /TV0 (TV0 为分组给药时测量的肿瘤体积,TVt为每次测量的肿瘤体积);IR=(1-给药物组的平均瘤重/模型组的平均瘤重)×100%。
统计学分析
采用SPSS 17.0 统计学软件进行数据分析,计量资料以均数±标准差(x±s)表示,肿瘤体积和肿瘤重量组间比较采用单因素方差分析(ANOVA),以P<0.05为差异有统计学意义。
结果
4.1 裸鼠一般情况和体重变化
各组在试验剂量下耐受性好,给药期间无死亡,随着给药时间延长各组裸鼠体重变化不大,没有统计学差异。
裸鼠TV、RTV的变化
结果示于以下表1中。
表1:各组裸鼠给药期间的TV(mm3)和RTV
注:与模型组比较,*P<0 .05,**P<0 .01;与物理混合组对照组比较,#P<0 .05,##P<0 .01。
如表1的结果所示,模型组裸鼠随着给药时间延长,TV、RTV明显增加,物理混合组随着给药时间的延长,TV和RTV基本保持不变,与模型组相比有显著性差异(P<0.01),共晶体组随着给药时间的延长,TV和RTV逐渐减小,与模型组相比有显著性差异(P<0.01),且与物理混合组相比有显著性差异,给药后7天P<0 .05,给药后14天P<0 .01。
给药后各组裸鼠的平均肿瘤重量和肿瘤抑制率
末次给药24小时后,处死裸鼠,模型组、物理混合组、共晶体组的平均瘤重分别为0.85±0.02g,0.18±0.02g和0.08±0.01g,物理混合组和共晶体组的平均瘤重显著低于模型组,有统计学差异(P<0 .01),共晶体组和物理混合物的平均瘤重也存在显著性差异(P<0.05)。物理混合组和共晶体组的抑瘤率(IR)分别为78.8%和90.6%。
以上描述了本发明优选实施方式,然其并非用以限定本发明。本领域技术人员对在此公开的实施方案可进行并不偏离本发明范畴和精神的改进和变化。
Claims (10)
1.一种来那替尼和汉黄芩素的复合物,其特征在于:所述复合物中来那替尼和汉黄芩素以共晶体的形式存在。
2.根据权利要求1的复合物,其特征在于,所述共晶体的X射线粉末衍射图谱中衍射角2θ包含在7.565°、9.295°、13.250°、19.030°、20.145°、22.078°、24. 788°以及27.500°的位置的衍射峰。
3.根据权利要求2所述的复合物,其特征在于,所述复合物的X射线粉末衍射图谱如下附图3所示。
4.根据权利要求2所述的复合物,其特征在于,所述复合物的差示扫描量热(DSC)法测定该共晶体的熔点为257.5℃。
5.根据权利要求1-4任一项所述的复合物,其特征在于,所述复合物中来那替尼和汉黄芩素的摩尔比为1:5至5:1,优选摩尔比为1:1。
6.一种制备权利要求1-5任一项的复合物的方法,其特征在于,所述制备方法为溶剂结晶法,其中所述溶剂为乙腈或含乙腈的混合溶剂。
7.根据权利要求6所述的方法,其中所述溶剂为乙腈或乙腈与甲醇、乙醇、乙酸乙酯、氯仿中的一种或两种以上按任意比例混合的混合溶剂系统,优选的溶剂为乙腈。
8.根据权利要求6-7任一项所述的方法,包括以下步骤:将来那替尼和汉黄芩素分别各自制备成第一饱和溶液和第二饱和溶液;将第一饱和溶液和第二饱和溶液分别过滤后混合,并静置挥发得到沉淀,将所述沉淀过滤、洗涤、干燥,得到白色结晶颗粒,即为来那替尼和汉黄芩素共晶体复合物。
9.一种预防和/或治疗癌症的药物组合物,所述药物组合物包括权利要求1-5任一项所述的复合物和药学上可接受的载体。
10.根据权利要求7所述的药物组合物,所述癌症为乳腺癌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010032446.8A CN111153882A (zh) | 2020-01-13 | 2020-01-13 | 一种来那替尼和汉黄芩素共晶体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010032446.8A CN111153882A (zh) | 2020-01-13 | 2020-01-13 | 一种来那替尼和汉黄芩素共晶体及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111153882A true CN111153882A (zh) | 2020-05-15 |
Family
ID=70562691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010032446.8A Pending CN111153882A (zh) | 2020-01-13 | 2020-01-13 | 一种来那替尼和汉黄芩素共晶体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111153882A (zh) |
-
2020
- 2020-01-13 CN CN202010032446.8A patent/CN111153882A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112047892B (zh) | 一种吉非替尼与3-羟基苯甲酸共晶体 | |
AU2016265922B2 (en) | A pharmaceutical co-crystal and use thereof | |
CN112047893B (zh) | 吉非替尼与水杨酸共晶体 | |
US20210171536A1 (en) | Compound of eoc315 mod.i crystal form and preparation method thereof | |
CN112010839A (zh) | 靶向丝/苏氨酸激酶抑制剂的晶型 | |
CN101323629B (zh) | 4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-甲基磷酸二乙酯 | |
CN111100117B (zh) | 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用 | |
CN111116462A (zh) | 一种瑞戈非尼和汉黄芩素共晶体及其应用 | |
CN111153882A (zh) | 一种来那替尼和汉黄芩素共晶体及其应用 | |
KR20240012513A (ko) | 세스퀴테르펜 유도체, 그의 약학적 조성물 및 그의 제조 방법과 용도 | |
CN113024557B (zh) | 一种Peganumine A生物碱结构简化物及其应用 | |
EP2902028A1 (en) | Drug composition for treating tumors and application thereof | |
WO2021047528A1 (zh) | 一个烟醇醚衍生物的马来酸盐及其晶型和应用 | |
CN110698491B (zh) | 2-(喜树碱-10-氧基)乙酰胺类化合物和应用 | |
US11111234B2 (en) | Salt of a quinazoline derivative-like tyrosine kinase inhibitor and crystal form thereof | |
CN114685512B (zh) | 一种伊布替尼-烟酸共晶及其制备方法 | |
CN101448833A (zh) | 5-氯-6-(2,6-二氟-4-[3-(甲基氨基)丙氧基]苯基)-N-[(1S)-2,2,2-三氟-1-甲基乙基][1,2,4]三唑并[1,5-a]嘧啶-7-胺盐的晶形 | |
AU2015392050B2 (en) | Fumarate of pyridylamine compound and crystals thereof | |
WO2022087763A1 (zh) | 含有索拉非尼游离碱和5-氟尿嘧啶的共晶体、药物组合物及其用途 | |
CN113234028B (zh) | 一种5-氟尿嘧啶与肌氨酸的共晶体及其制备方法与用途 | |
CN114149426A (zh) | 帕博西尼药物共晶及其制备方法 | |
WO2022199708A1 (zh) | 卢美哌隆药用盐、制备方法、含其的药物组合物及应用 | |
EP4306115A1 (en) | Pharmaceutical composition, and preparation method therefor and application thereof | |
CN114601831A (zh) | 乐伐替尼分子复合物及其制备方法 | |
CN114957137A (zh) | N-(1,2,3,6-四氢嘧啶-4-基)-2-苯基乙酰胺类化合物及其制备与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200515 |